06127 JOINN
- 9.060
- -0.390-4.13%
JOINN News
A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.
① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.
Joinn Laboratories (06127.HK) spent 0.885 million yuan on December 13 to repurchase 0.05 million shares.
On December 13, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 13, 2024, the company spent 0.885 million yuan to repurchase 0.05 million shares on the Shanghai Stock Exchange, with a repurchase price of 17.7 yuan per share.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stocks unusual movement | CRO concept stocks expanded their gains, wuxi apptec (02359) surged 12% at one point. It is rumored that US legislators are considering making changes to the bioterrorism law.
CRO concept stocks further expanded their gains. As of the time of publication, wuxi apptec (02359) rose by 10%, trading at 55 Hong Kong dollars; pharmaron (03759) increased by 8.12%, trading at 14.64 Hong Kong dollars; wuxi bio (02269) went up by 7.02%, trading at 17.6 Hong Kong dollars.
Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.
Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.
Joinn Laboratories(China)Co.Ltd (SHSE:603127 Shareholders Incur Further Losses as Stock Declines 3.8% This Week, Taking Three-year Losses to 75%
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks
Joinn Laboratories (603127.SH): Cumulative repurchase of 0.2806% A-share shares.
On November 1, Gelunhui reported that Joinn Laboratories (603127.SH) announced that as of October 31, 2024, the company has cumulatively repurchased 2,103,100 shares of A shares through centralized auction trading, accounting for 0.2806% of the total shares on the date of this announcement. The highest repurchase price was RMB 18.15 per share, and the lowest repurchase price was RMB 13.20 per share, with a total amount of RMB 33,195,984.40 (excluding transaction costs).
Joinn Laboratories' Q3 Profit Slides 58%
Zhaoyan Pharmaceutical: Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Joinn Laboratories (06127) plans to invest no more than 0.1 billion yuan in setting up the second phase fund of the service trade.
Joinn Laboratories (06127) announced that, in order to fulfill the policy mission of national funds, it will fully support the company's business development and provide...
Express News | Joinn Laboratories China - Qtrly Rev RMB485.8 Mln
Express News | Joinn Laboratories China - Qtrly Net Profit Attributable RMB99.4 Mln
JOINN: 2024 THIRD QUARTERLY REPORT
Joinn Laboratories (06127.HK) nominated Luo Xi as an executive director.
Joinn Laboratories (06127.HK) announced on October 30 that the board of directors recently received Dr. Yao Dalin's resignation letter. As a result, Dr. Yao resigned as an executive director and deputy general manager of the company due to work arrangements. The board of directors resolved to nominate Ms. Luo Xi as an executive director of the company. The appointment of Ms. Luo is subject to approval by the shareholders in the first extraordinary general meeting of the company in 2025 in the form of an ordinary resolution.
Express News | Joinn Laboratories China Co Ltd - Yao Dalin Resigned as Executive Director
No Data
